64 completed, 8 unknown, 5 not yet recruiting, 5 recruiting. 90 Phase 1, 20 Phase 2.
Follow Neuralgia: new trials by email Literature Review of Neuralgia trials Research Report on Neuralgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Simultaneous Engagement of Networks for Alleviating Pain (SENAP) PFM-guided cortical stimulation - Neuropathic Pain, Postherpetic Neuralgia | Phase 1 | Not yet recruiting | University of Minnesota | 20 | 2027-01-01 | 2026-11-03 |
| Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain Green Tea Leaf Extract Decaffeinated, Placebo Control - Neuropathic Pain, Cancer Treatment | Phase 1 | Not yet recruiting | University of Alabama at Birmingham | 20 | 2026-09-30 | 2026-08-21 |
| OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis glibenclamide, Placebo - Multiple Sclerosis, Neuropathic Pain | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 10 | 2026-09-01 | 2025-10-28 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants Y-4 tablet, Pregabalin capsule, Riluzole tablet - Healthy Male and Female Subjects | Phase 1 | Not yet recruiting | Neurodawn Pharmaceutical Co., Ltd. | 11 | 2026-06-30 | 2026-06-01 |
| Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury EC5026 oral tablet, Placebo oral tablet - Spinal Cord Injuries, Neuropathic Pain | Phase 1 | Recruiting | EicOsis Human Health Inc. | 36 | 2026-05-01 | 2026-07-10 |
| A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia BHV-7000, Placebo - Familial Erythromelalgia | Phase 1 | Active not recruiting | Biohaven Therapeutics Ltd. | 5 | 2026-01-15 | 2026-10-29 |
| Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults ASCT-83, Placebo - Neuropathic Pain | Phase 1 | Recruiting | Alcamena Stem Cell Therapeutics | 72 | 2026-01-06 | 2026-06-16 |
| Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy C-1101, Placebo: Sterile Saline - Lumbosacral Radicular Pain, Sciatic Radiculopathy | Phase 1 | Recruiting | Consano Bio | 24 | 2025-12-03 | 2026-10-21 |
| Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI CBD/CBD-A, Placebo - SCI - Spinal Cord Injury, Neuropathic Pain | Phase 1 / Phase 2 | Completed | University of Miami | 6 | 2025-06-16 | 2026-08-14 |
| Ilioinguinal Nerve Block With Local Anesthetic vs. Placebo in Inguinal Hernia Repair Under Spinal Anesthesia Ilioinguinal/iliohypogastric Nerve Block, Ilioinguinal/iliohypogastric with Placebo Block - Inguinal Hernias | Phase 1 | Active not recruiting | Makassed General Hospital | 100 | 2025-06-01 | 2025-07-03 |
| A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers LY4286533, placebo - Neuropathic Pain | Phase 1 | Completed | 4E Therapeutics | 40 | 2025-04-18 | 2026-09-08 |
| Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects Ketamir-2, Placebo - Healthy Adult Participants | Phase 1 | Completed | MIRA Pharmaceuticals | 57 | 2025-03-20 | 2026-08-27 |
| Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain Resiniferatoxin - Morton's Neuroma | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 3 | 2025-03-13 | 2026-04-13 |
| Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain PIPE-791, Placebo - Chronic Osteoarthritis Pain, Chronic Low Back Pain | Phase 1 | Completed | Contineum Therapeutics | 43 | 2025-02-04 | 2026-03-18 |
| PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin [18F]FTC-146 - Nerve Pain, Neuropathic Pain | Phase 1 | Not yet recruiting | Stanford University | 200 | 2024-10-01 | 2024-09-19 |
| (2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain Ketamine, (2R,6R)-hydroxynorketamine, Saline - Pain, Neuropathic | Phase 1 / Phase 2 | Recruiting | Rush University Medical Center | 25 | 2024-09-19 | 2026-08-03 |
| Noninvasive Modulation of Chronic Neuropathic Pain Active stimulation using low-frequency ultrasonic transducer, Sham stimulation using low-frequency ultrasonic transducer - Neuropathic Pain, Chronic Pain | Phase 1 / Phase 2 | Withdrawn | University of Utah | 2024-02-10 | 2025-05-22 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects AJH-2947 tablets or placebo - Healthy Volunteers, Chronic Pain Syndrome | Phase 1 | Completed | JMackem Co., Ltd | 76 | 2023-12-05 | 2026-08-13 |
| Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers AFA-281 - Pain, Neuropathic, Pain, Inflammatory | Phase 1 | Completed | Afasci Inc | 64 | 2023-04-11 | 2025-10-21 |
Showing 20 of 90. Sign in to see all of them.
Chronic Pain (14) · Neuralgia, Postherpetic (14) · Pain (12) · Sciatica (11) · Low Back Pain (5) · Diabetic Neuropathies (4) · Marijuana Abuse (4) · Nociceptive Pain (4) · Pain, Postoperative (4) · Spinal Cord Injuries (4) · Morton Neuroma (3) · Movement Disorders (3) · Osteoarthritis (3) · Peripheral Nerve Injuries (3)
Nervous System Diseases (90) · Neurologic Manifestations (90) · Neuromuscular Diseases (90) · Pathological Conditions, Signs and Symptoms (90) · Signs and Symptoms (90) · Peripheral Nervous System Diseases (89) · Pain (78) · Mononeuropathies (11) · Sciatic Neuropathy (11) · Central Nervous System Diseases (10) · Musculoskeletal Diseases (8) · Trauma, Nervous System (7) · Joint Diseases (6) · Pathologic Processes (6)
Lidocaine (5) · Pregabalin (4) · 6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo(d)thiazol-2(3H)-one (3) · Nerve Growth Factor (3) · Sodium Chloride (3) · nabiximols (3) · vixotrigine (3) · Capsaicin (2) · Clonazepam (2) · D-methadone (2) · Drug Evaluation (2) · Gabapentin (2) · Ondansetron (2) · tariquidar (2) · 6-hydroxynorketamine (1)
Biogen (7) · Stanford University (4) · Center for Medicinal Cannabis Research (3) · GL Pharm Tech Corporation (3) · University Children's Hospital, Zurich (3) · Washington University School of Medicine (3) · GlaxoSmithKline (2) · IlDong Pharmaceutical Co Ltd (2) · Merck Sharp & Dohme LLC (2) · Relmada Therapeutics, Inc. (2) · University Hospital, Clermont-Ferrand (2) · iN Therapeutics Co., Ltd. (2) · 4E Therapeutics (1) · Abide Therapeutics (1) · Afasci Inc (1)
United States (36) · Australia (7) · South Korea (7) · Canada (6) · Switzerland (6) · United Kingdom (6) · Netherlands (3) · Belgium (2) · Denmark (2) · France (2) · Israel (2) · Germany (1) · Lebanon (1) · Moldova (1) · Portugal (1)
Simon Haroutounian, PhD (3) · Min-Gul Kim, Ph.D. (2) · Adelaide A. Hebert, MD (1) · Ahmar U Zaidi, MD (1) · Alexander Herman, MD (1) · Alexander K Glaros, MD (1) · Allan V Danielsen, MD (1) · Anand Veeravagu (1) · Anand Veeravagu, MD (1) · Andrew J Mannes, M.D. (1) · Asokumar Buvanendran, MD (1) · Barth L Wilsey, M.D. (1)
PMID 35295458, PMID 11145807, PMID 12384756, PMID 12897484, PMID 15115710, PMID 15454701, PMID 16192528, PMID 16371894, PMID 16466122, PMID 18362604, PMID 19356391, PMID 19387178, PMID 19717722, PMID 21185118, PMID 25218827, PMID 25962165, PMID 26032776, PMID 28158151, PMID 29229209, PMID 31626118, PMID 34718774, PMID 40134759, PMID 41090674, PMID 42370792, PMID 9854752
2014 (1), 2015 (1), 2017 (1), R43AR052998 (1), R44DA018515 (1), R44NS145934 (1), U44NS115692 (1)